Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 2
2012 3
2013 3
2014 3
2015 1
2016 3
2019 2
2020 3
2021 3
2022 2
2023 6
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.
Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, Razaq M, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G; ATALANTE-1 study group. Besse B, et al. Ann Oncol. 2023 Oct;34(10):920-933. doi: 10.1016/j.annonc.2023.07.006. Epub 2023 Sep 11. Ann Oncol. 2023. PMID: 37704166 Free article. Clinical Trial.
[Sinonasal cancers].
Ferrand FR, Thariat J, Verillaud B, Le Clerc N. Ferrand FR, et al. Rev Prat. 2022 Jan;72(1):71-77. Rev Prat. 2022. PMID: 35258260 French.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
[Disseminated intravascular coagulation in solid tumours].
Ferrand FR, Garcia-Hejl C, Moussaid Y, Schernberg A, Bidard FC, Pavic M, Khenifer S, Stoclin A. Ferrand FR, et al. Bull Cancer. 2014 Jun;101(6):580-92. doi: 10.1684/bdc.2014.1959. Bull Cancer. 2014. PMID: 24977447 Review. French.
Twelve years after: The french national network on rare head and neck tumours (REFCOR).
Gasne C, Atallah S, Dauzier E, Thariat J, Fakhry N, Verillaud B, Classe M, Vergez S, Moya-Plana A, Costes-Martineau V, Righini C, de Gabory L, Digue L, Dupin C, Ferrand FR, Even C, Baujat B; REFCOR members. Gasne C, et al. Among authors: ferrand fr. Oral Oncol. 2024 Apr;151:106762. doi: 10.1016/j.oraloncology.2024.106762. Epub 2024 Mar 20. Oral Oncol. 2024. PMID: 38513311 Free article.
Disseminated and circulating tumor cells in gastrointestinal oncology.
Bidard FC, Ferrand FR, Huguet F, Hammel P, Louvet C, Malka D, Boige V, Ducreux M, Andre T, de Gramont A, Mariani P, Pierga JY. Bidard FC, et al. Among authors: ferrand fr. Crit Rev Oncol Hematol. 2012 May;82(2):103-15. doi: 10.1016/j.critrevonc.2011.05.008. Epub 2011 Jun 15. Crit Rev Oncol Hematol. 2012. PMID: 21680197 Free article. Review.
Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method.
Thariat J, Ferrand FR, Fakhry N, Even C, Vergez S, Chabrillac E, Sarradin V, Digue L, Troussier I, Bensadoun RJ. Thariat J, et al. Among authors: ferrand fr. Eur Ann Otorhinolaryngol Head Neck Dis. 2024 Aug;141(4):221-226. doi: 10.1016/j.anorl.2023.11.006. Epub 2023 Nov 28. Eur Ann Otorhinolaryngol Head Neck Dis. 2024. PMID: 38030445 Review.
Survival outcomes, prognostic factors, and effect of adjuvant radiotherapy and prophylactic neck dissection in salivary acinic cell carcinoma: A prospective multicenter REFCOR study of 187 patients.
Chatelet F, Ferrand FR, Atallah S, Thariat J, Mouawad F, Fakhry N, Malard O, Even C, de Monès E, Uro-Coste E, Benzerdjeb N, Hans S, Testelin S, Mauvais O, Evrard D, Bastit V, Salas S, Espitalier F, Classe M, Digue L, Doré M, Wong S, Dupin C, Nguyen F, Bettoni J, Lapierre A, Colin E, Philouze P, Vergez S, Baujat B, Herman P, Verillaud B; REFCOR members. Chatelet F, et al. Among authors: ferrand fr. Eur J Cancer. 2023 May;185:11-27. doi: 10.1016/j.ejca.2023.02.020. Epub 2023 Mar 2. Eur J Cancer. 2023. PMID: 36947928
38 results